Jul 28, 2022 6:45 am EDT Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics
Jul 26, 2022 4:38 pm EDT Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Jul 22, 2022 8:30 am EDT Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
Jul 5, 2022 6:45 am EDT Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects
Jun 27, 2022 6:53 am EDT Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
May 31, 2022 4:30 pm EDT Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Apr 25, 2022 6:45 am EDT Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Mar 21, 2022 6:45 am EDT Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th
Mar 18, 2022 6:45 am EDT Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)